menu
    • menu

    Company profile for Osmol Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Osmol Therapeutics, Inc. is a development stage biopharma company based in New Haven, Connecticut advancing a novel treatment to prevent chemotherapy induced peripheral neuropathy and other disease driven by calcium dysregulation. Osmol was founded by Dr. Barbara Ehrlich, Professor of Pharmacology and of Cellular and Molecular Physiology, Yale School of Medicine. Her research on neuronal calcium sensor-1 (NCS1), a critical ca...
    Osmol Therapeutics, Inc. is a development stage biopharma company based in New Haven, Connecticut advancing a novel treatment to prevent chemotherapy induced peripheral neuropathy and other disease driven by calcium dysregulation. Osmol was founded by Dr. Barbara Ehrlich, Professor of Pharmacology and of Cellular and Molecular Physiology, Yale School of Medicine. Her research on neuronal calcium sensor-1 (NCS1), a critical calcium binding protein that regulates intracellular calcium levels, forms the basis of Osmol’s CIPN treatment, OSM-0205 and future potential NCS1 therapeutics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Osmol TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    33 WHITNEY AVE, New Haven, Connecticut 06510
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://osmoltherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Osmol Therapeutics E.U. Patent for Neuropathy Therapy
    Osmol Therapeutics E.U. Patent for Neuropathy Therapy

    16 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/16/3099757/0/en/Osmol-Therapeutics-E-U-Patent-Allowance-for-Novel-Therapy-Targeting-Chemotherapy-induced-Neuropathy.html

    GLOBENEWSWIRE
    16 Jun 2025
    Share Share
    Osmol Therapeutics Appoints Christopher S. Eklund to its Board of Directors
    Osmol Therapeutics Appoints Christopher S. Eklund to its Board of Directors

    15 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/15/2882347/0/en/Osmol-Therapeutics-Appoints-Christopher-S-Eklund-to-its-Board-of-Directors.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
    Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer

    04 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/04/2839522/0/en/Osmol-Therapeutics-Appoints-Ron-Weitzman-M-D-as-Interim-Chief-Medical-Officer.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    FDA Notifies Osmol that the First-in-Human Phase 1 Clinical Trial of OSM-0205
    FDA Notifies Osmol that the First-in-Human Phase 1 Clinical Trial of OSM-0205

    18 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230918920134/en

    BUSINESSWIRE
    18 Sep 2023
    Share Share
    Osmol Appoints Teresa Bitetti at Takeda to the Board of Directors
    Osmol Appoints Teresa Bitetti at Takeda to the Board of Directors

    08 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220908005227/en

    BUSINESSWIRE
    08 Sep 2022
    Share Share
    Osmol Closes Series A-1 Funding to Prevent Chemotherapy-Induced Neuropathy
    Osmol Closes Series A-1 Funding to Prevent Chemotherapy-Induced Neuropathy

    12 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220412005190/en

    BUSINESSWIRE
    12 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search